Mark L. Freedman
Canada, Ontario - Pharma Medica Research Inc. 4770 Sheppard Ave E
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Mark L. Freedman as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:03 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07228325 · Comparative PK/PD of FMXIN002 and EpiPen, in Healthy Adults With Allergic RhinitisNasus Pharma · enrolling by invitation · Anaphylaxis, Allergy
- Ph1NCT06987773 · Study on Sapropterin Dihydrochloride Oral Suspension in Healthy Subjects Under Fed ConditionsAPR Applied Pharma Research s.a. · completed · Bioequivalence · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:03 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:03 UTC. The ranking covers the 200 most relevant of 4 PubMed records, and a shared surname and initials can bring in a namesake. All 4 on PubMed
- Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma.Nat Commun · 2021152 citationsRCR 7.1
- 20 citationsRCR 0.6
- Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate Cancer.JCO Precis Oncol · 202216 citationsRCR 0.9
- Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancer.Cell Rep Med · 202511 citationsRCR 2.1